TCGA-63-A5MY-01A-11R-A26W-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 63
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.580
- E2F_TARGETS+0.450
- G2M_CHECKPOINT+0.360
- MYC_TARGETS_V1+0.350
- OXIDATIVE_PHOSPHORYLATION+0.320
- SPERMATOGENESIS+0.280
- UNFOLDED_PROTEIN_RESPONSE+0.220
- DNA_REPAIR+0.210
- MTORC1_SIGNALING+0.200
- GLYCOLYSIS+0.170
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.640
- INTERFERON_GAMMA_RESPONSE-0.600
- ALLOGRAFT_REJECTION-0.570
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.520
- COMPLEMENT-0.470
- KRAS_SIGNALING_UP-0.470
- INFLAMMATORY_RESPONSE-0.450
- HEDGEHOG_SIGNALING-0.430
- IL6_JAK_STAT3_SIGNALING-0.430
- TGF_BETA_SIGNALING-0.430
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-33-4532-01A-01R-1201-07 | — | cohortSQ2 | 0.940 |
| 2 | SRR8518240 | — | E | 0.938 |
| 3 | C3L-00993 | — | cohortSQ1 | 0.937 |
| 4 | SRR8518239 | — | E | 0.935 |
| 5 | TCGA-CQ-6225-01A-11R-1915-07 | — | — | 0.926 |
| 6 | BS_NKEAAFMW | medulloblastoma | — | 0.922 |
| 7 | 64935b9c-623d-40d4-bd89-f2af006b1f92 | — | — | 0.920 |
| 8 | TCGA-QK-A6VB-01A-12R-A34R-07 | — | — | 0.916 |
| 9 | SRR12475110 | — | — | 0.916 |
| 10 | MDT-AP-0421 | Med | Medulloblastoma | 0.916 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.580 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.450 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.360 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.350 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.320 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.280 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.220 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.210 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.170 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.120 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.080 | Inavolisib | — uncovered |
| PEROXISOME | 0.030 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.020 | Inavolisib | — uncovered |
| HYPOXIA | 0.020 | Idelalisib | — uncovered |